Immunic Inc. traded at $5.36 this Thursday May 12th, increasing $0.12 or 2.29 percent since the previous trading session. Looking back, over the last four weeks, Immunic Inc. gained 50.28 percent. Over the last 12 months, its price fell by 57.49 percent. Looking ahead, we forecast Immunic Inc. to be priced at 5.96 by the end of this quarter and at 5.54 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
BioMarin Pharmaceutical 76.05 0.37 0.48% 0.59%
Dynavax Technologies 9.05 1.13 14.20% 23.47%
Enanta Pharmaceuticals 50.93 0.50 0.99% 1.25%
Epizyme 0.54 0.01 1.08% -93.74%
Intercept Pharmaceuticals 17.33 -0.12 -0.66% 0.55%
Insmed 17.86 0.67 3.87% -29.93%
Mirati Therapeutics 54.88 1.53 2.87% -64.54%
Omeros 3.26 0.31 10.51% -82.21%
OraSure Technologies 5.17 0.03 0.51% -44.33%
Quidel 91.09 2.03 2.28% -24.05%
Ultragenyx Pharmaceutical 51.08 0.20 0.39% -51.99%
Regulus Therapeutics 0.22 -0.04 -15.45% -73.83%
Revance Therapeutics 13.20 -0.02 -0.15% -52.74%
United Therapeutics 182.05 2.56 1.43% -6.88%
Immunic Inc. 5.36 0.12 2.29% -57.49%
Xoma 17.55 0.50 2.93% -41.54%

Indexes Price Day Year
USND 11692 321.17 2.82% -12.94%
US2000 1780 40.95 2.35% -19.97%

Immunic Inc.
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.